Compare Amylx Pharmaceuticals Inc (AMLX) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Cenovus Energy Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Cenovus Energy Inc trades at $26.91 (market cap $49.07B). The key difference: Cenovus Energy Inc is far larger — about 24.8× Amylx Pharmaceuticals Inc's market cap, and Cenovus Energy Inc pays a 2.35% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CVE | |
|---|---|---|
Market Cap | $1.98B | $49.07B |
Sector | Health | Energy |
52-Week High | $18.70 | $31.80 |
52-Week Low | $7.64 | $13.96 |
Enterprise Value | $1.70B | $56.95B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Cenovus Energy (CVE) trades at $26.40, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.93 and net income margin of 8.94%, supported by three consecutive quarterly earnings beats. Recent news highlights its 85% annual rally, driven by oil price gains and operational synergies from MEG Energy.
The outlook remains positive given its low-cost assets and integrated model, though risks include oil price volatility and execution of growth plans. Analyst consensus is mixed with 40.7% buy ratings, reflecting cautious optimism amid energy sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
